AssetMark Inc’s Vaxcyte PCVX Stock Holding History

AssetMark Inc’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$108K	Sell	1,851 -28	-1%	-$1.52K	﹤0.01%	1604
2026 Q1	$109K	Sell	1,879 -16	-0.8%	-$869	﹤0.01%	1514
2025 Q4	$87.4K	Sell	1,895 -11,427	-86%	-$511K	﹤0.01%	1541
2025 Q3	$480K	Sell	13,322 -288	-2%	-$9.54K	﹤0.01%	1108
2025 Q2	$442K	Sell	13,610 -814	-6%	-$26.7K	﹤0.01%	1071
2025 Q1	$545K	Buy	14,424 +13,648	+1,759%	+$1.09M	﹤0.01%	965
2024 Q4	$63.5K	Buy	776 +775	+77,500%	+$77K	﹤0.01%	1356
2024 Q3	$114	Buy	+1	New	+$90	﹤0.01%	2199

Other funds holding PCVX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

AssetMark Inc's PCVX Position: Q2 2026 in Review

AssetMark Inc reduced its Vaxcyte (PCVX) stake by 1.5% in Q2 2026, selling an estimated $1.52K and leaving 1,851 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

AssetMark Inc first reported a position in PCVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $545K in Q1 2025. 69 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

AssetMark Inc held 1,851 shares of Vaxcyte worth $108K as of Q2 2026.
AssetMark Inc sold 28 Vaxcyte shares in Q2 2026, an estimated $1.52K.
Vaxcyte made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1604 holding.
AssetMark Inc first reported a position in Vaxcyte in Q3 2024 and has held it in 8 quarters since.
AssetMark Inc's Vaxcyte position peaked at $545K in Q1 2025.
69 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.